Cell Therapy Manufacturing: Getting it Right From the Start

March 2017

(This course is run by Cell Therapy Catapult and supported by UCL. This course is not UCL accredited).

Draft Agenda here

Cell and gene therapy have emerged as two of the most significant therapeutic modalities of the 21st century. Both independently and in combination (genetically modified cells), these technologies are starting to produce transformative therapies for patients across a broad range of medical fields including cancer immunotherapy and regenerative medicine. The
need for scalable cost-effective manufacturing is a key requirement for the field.

The course objective is to challenge delegates to think about the commercial product, market, and process from the outset and to use that information to inform the process development and manufacturing strategy for clinical trials and routine manufacture. This will be achieved through lectures from a wide range of experienced, successful, international industrialists building on a solid framework of regulatory requirements. The experience gained will be put to use in developing case study processes and understanding how these processes relate to cost of goods models and what factors most impact the cost of goods.

A final presentation to the panel of international industrialists with feedback will round off the training course experience.

Who should attend?

Stakeholders in the cell and gene therapy sector who need to understand the manufacturing challenges and/or are planning or progressing a therapy through the R&D and translation phases and into routine clinical practice and commercialization. The course comprehensively covers both the service (autologous) and universal (allogeneic) approaches to whole bioprocessing.

Previous company delegates include; GE Healthcare, GlaxoSmithKline, Johnson & Johnson, Medical Research Council, Plasticell, ReNeuron, Sanofi, Smith & Nephew and UCL Hospitals.


Day 1
• Course overview
• Introduction to the cell and gene therapy industry
• Cell and gene therapy platforms
• Progress and challenges in manufacturing
• Process development

Day 2
• End-to-end supply chain
• Cell therapy manufacturing
• Cost of goods
• Commercial case study
• Storage and distribution

Day 3
• ATMP regulatory pathway
• Overview of clinical landscape
• Gene therapy manufacturing
• Commercial case study
• Manufacturing ecosystem

Module Leaders

Prof Chris Mason, UCL
Dr Stephen Ward, Cell and Gene Therapy Catapult
Dr Angela Osborne, eXmoor pharma concepts ltd

Confirmed Industrial Expert Speakers:

Anthony Davies, Dark Horse Consulting
Suzy Farid, UCL
Farzin Farzaneh, King’s College London
Thomas Fellner, Lonza
Lucy Foley, Centre for Process Innovation
Paddy Ginty, GSK
Sharon Grimster, ReNeuron
Michael Linden, Pfizer
Geoff MacKay, AVROBIO
Otto Merten, Genethon
James Miskin, Oxford Biomedica
David Smith, Lonza
Jan Thirkettle, Freeline Therapeutics
Kim Warren, CCRM
Dan Williams, Adaptimmune
David Wilson, Fisher Bioservices
David Venables, Synpromics

A networking dinner will be held on the first evening.

For further information and bookings please contact:
E: mbi-training@ucl.ac.uk
T: +44 (0) 20 7679 9619 l +44 (0) 203 549 5619

MBI® logo CGT amc Logo

Page last modified on 16 mar 16 15:05